MYC and hepatocellular carcinoma: To further understand whether Fraxini’s down-regulation of c-Myc expression played a role in Fraxini’s anticancer activity, we compared the antiproliferative activity of Fraxini in two HCC cell lines (Hep3B and PLC) and hepatoma HepG2 cells.